

Tadaaki Yamada

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5719650/publications.pdf>

Version: 2024-02-01

155
papers

3,803
citations

117625

34
h-index

149698

56
g-index

156
all docs

156
docs citations

156
times ranked

5245
citing authors

#	ARTICLE	IF	CITATIONS
1	Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Clinical Cancer Research</i> , 2009, 15, 6630-6638.	7.0	255
2	AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. <i>Nature Communications</i> , 2019, 10, 259.	12.8	223
3	Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort. <i>Journal of Thoracic Oncology</i> , 2011, 6, 2011-2017.	1.1	196
4	EGFR-TKI Resistance Due to <i>BIM</i> Polymorphism Can Be Circumvented in Combination with HDAC Inhibition. <i>Cancer Research</i> , 2013, 73, 2428-2434.	0.9	151
5	Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells. <i>Clinical Cancer Research</i> , 2012, 18, 3592-3602.	7.0	104
6	Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 1362.	2.4	102
7	Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in <i>EGFR</i> Mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 2260-2269.	7.0	101
8	Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in <i>EGFR</i> -T790M Mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 174-183.	7.0	93
9	Tumor Neovascularization and Developments in Therapeutics. <i>Cancers</i> , 2019, 11, 316.	3.7	85
10	Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer. <i>Cancer Medicine</i> , 2019, 8, 1521-1529.	2.8	82
11	Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in <i>EGFR</i> -Mutant Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2149-2157.	4.1	81
12	Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor-Induced Tyrosine Kinase Inhibitor Resistance in <i>EGFR</i> Mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 1663-1671.	7.0	81
13	Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of <i>ALK</i> Mutation Status. <i>Cancer Research</i> , 2019, 79, 1658-1670.	0.9	79
14	ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in <i>EGFR</i> -Mutated Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2244-2256.	7.0	75
15	Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 450.	2.4	72
16	Histone Deacetylase 3 Inhibition Overcomes <i>BIM</i> Deletion Polymorphism-Mediated Osimertinib Resistance in <i>EGFR</i> -Mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 3139-3149.	7.0	69
17	Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. <i>Nature Communications</i> , 2020, 11, 4607.	12.8	69
18	Ligand-triggered resistance to molecular targeted drugs in lung cancer: Roles of hepatocyte growth factor and epidermal growth factor receptor ligands. <i>Cancer Science</i> , 2012, 103, 1189-1194.	3.9	64

#	ARTICLE	IF	CITATIONS
19	Notch3-dependent β -catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC. <i>Nature Communications</i> , 2018, 9, 3198.	12.8	61
20	Overexpression of manganese superoxide dismutase by N-acetylcysteine in hyperoxic lung injury. <i>Respiratory Medicine</i> , 2007, 101, 800-807.	2.9	57
21	High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells. <i>Oncotarget</i> , 2016, 7, 3847-3856.	1.8	56
22	E7080, a Multi-Tyrosine Kinase Inhibitor, Suppresses the Progression of Malignant Pleural Mesothelioma with Different Proangiogenic Cytokine Production Profiles. <i>Clinical Cancer Research</i> , 2009, 15, 7229-7237.	7.0	55
23	Dual Inhibition of Met Kinase and Angiogenesis to Overcome HGF-Induced EGFR-TKI Resistance in EGFR Mutant Lung Cancer. <i>American Journal of Pathology</i> , 2012, 181, 1034-1043.	3.8	55
24	Pleural Mesothelioma Instigates Tumor-Associated Fibroblasts To Promote Progression via a Malignant Cytokine Network. <i>American Journal of Pathology</i> , 2011, 179, 1483-1493.	3.8	54
25	MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR-mutant Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 506-515.	4.1	52
26	The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 847-853.	2.8	52
27	The EGFR Ligands Amphiregulin and Heparin-Binding EGF-like Growth Factor Promote Peritoneal Carcinomatosis in CXCR4-Expressing Gastric Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 3619-3630.	7.0	46
28	Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. <i>Oncotarget</i> , 2014, 5, 4920-4928.	1.8	46
29	Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 102.	2.4	42
30	Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors. <i>PLoS ONE</i> , 2013, 8, e84700.	2.5	41
31	Hepatocyte Growth Factor Induces Resistance to Anti-Epidermal Growth Factor Receptor Antibody in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 272-280.	1.1	37
32	Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 17-25.	4.1	37
33	Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1078-1085.	1.1	34
34	Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation. <i>Journal of Thoracic Oncology</i> , 2014, 9, 775-783.	1.1	34
35	Safety and Usefulness of Cryobiopsy and Stamp Cytology for the Diagnosis of Peripheral Pulmonary Lesions. <i>Cancers</i> , 2019, 11, 410.	3.7	34
36	mTOR Inhibitors Control the Growth of EGFR Mutant Lung Cancer Even after Acquiring Resistance by HGF. <i>PLoS ONE</i> , 2013, 8, e62104.	2.5	32

#	ARTICLE	IF	CITATIONS
37	Genetically engineered humanized anti- α -ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells. <i>Cancer Science</i> , 2011, 102, 2157-2163.	3.9	31
38	Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2021, 161, 26-33.	2.0	31
39	Thioredoxin-1 protects against hyperoxia-induced apoptosis in cells of the alveolar walls. <i>Pulmonary Pharmacology and Therapeutics</i> , 2007, 20, 650-659.	2.6	29
40	TGF- β 2-dependent reprogramming of amino acid metabolism induces epithelial-mesenchymal transition in non-small cell lung cancers. <i>Communications Biology</i> , 2021, 4, 782.	4.4	29
41	The novel phosphoinositide 3-kinase mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor. <i>International Journal of Cancer</i> , 2013, 133, 505-513.	5.1	28
42	Amphiregulin triggered epidermal growth factor receptor activation confers <i>in vivo</i> crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors. <i>Cancer Science</i> , 2017, 108, 53-60.	3.9	28
43	Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. <i>Cancer Letters</i> , 2008, 265, 55-66.	7.2	26
44	A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma. <i>Cancer Research</i> , 2017, 77, 153-163.	0.9	26
45	Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion-Positive Tumor Cells in a Brain Metastasis Model. <i>Clinical Cancer Research</i> , 2018, 24, 2357-2369.	7.0	25
46	Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients. <i>Scientific Reports</i> , 2020, 10, 17495.	3.3	24
47	Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations. <i>Oncogene</i> , 2013, 32, 4427-4435.	5.9	23
48	Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study. <i>Oncolimmunology</i> , 2021, 10, 1950411.	4.6	22
49	Lysophosphatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells through lysophosphatidic acid receptors, LPA ₁ and LPA ₂ . <i>Cancer Science</i> , 2008, 99, 1603-1610.	3.9	20
50	Intensification therapy with anti-parathyroid hormone-related protein antibody plus zoledronic acid for bone metastases of small cell lung cancer cells in severe combined immunodeficient mice. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 119-126.	4.1	20
51	Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway. <i>Cancer Science</i> , 2017, 108, 1378-1385.	3.9	20
52	Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer. <i>Cancer Science</i> , 2013, 104, 1640-1646.	3.9	19
53	Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2019, 8, 450-460.	2.8	18
54	Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 227-234.	2.8	17

#	ARTICLE	IF	CITATIONS
55	Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial. <i>Oncologist</i> , 2019, 24, 593-e170.	3.7	17
56	The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1061-1076.	1.1	17
57	Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 630136.	2.8	17
58	Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer. <i>Diagnostics</i> , 2022, 12, 423.	2.6	17
59	Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma. <i>Cancer Research</i> , 2015, 75, 4188-4197.	0.9	16
60	Plasma membrane anchored nanosensor for quantifying endogenous production of H ₂ O ₂ in living cells. <i>Biosensors and Bioelectronics</i> , 2021, 179, 113077.	10.1	16
61	Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation. <i>Cancer Science</i> , 2017, 108, 696-703.	3.9	15
62	A Bone Metastasis Model With Osteolytic and Osteoblastic Properties of Human Lung Cancer ACC-LC-319/bone2 in Natural Killer Cell-Depleted Severe Combined Immunodeficient Mice. <i>Oncology Research</i> , 2009, 17, 581-591.	1.5	15
63	E7080 Suppresses Hematogenous Multiple Organ Metastases of Lung Cancer Cells with Nonmutated Epidermal Growth Factor Receptor. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1218-1228.	4.1	14
64	Organ-specific efficacy of HSP90 inhibitor in multiple-organ metastasis model of chemorefractory small cell lung cancer. <i>International Journal of Cancer</i> , 2016, 138, 1281-1289.	5.1	14
65	Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 947-956.	4.1	14
66	Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 526-532.	1.9	13
67	Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients. <i>Medical Oncology</i> , 2020, 37, 111.	2.5	13
68	Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 2033.	2.4	13
69	Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer. <i>Cancer Letters</i> , 2021, 522, 119-128.	7.2	13
70	HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features. <i>Npj Precision Oncology</i> , 2022, 6, 5.	5.4	13
71	Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma. <i>Oncology Reports</i> , 2014, 31, 1109-1115.	2.6	12
72	A case of aseptic meningitis without neck rigidity occurring in a metastatic melanoma patient treated with ipilimumab. <i>European Journal of Dermatology</i> , 2017, 27, 193-194.	0.6	12

#	ARTICLE	IF	CITATIONS
73	Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report. <i>BMC Pulmonary Medicine</i> , 2018, 18, 193.	2.0	12
74	Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study. <i>Translational Lung Cancer Research</i> , 2021, 10, 3582-3593.	2.8	12
75	Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients. <i>Cancers</i> , 2019, 11, 282.	3.7	11
76	Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 735-741.	2.3	10
77	Comparing three different anti-PD-L1 antibodies for immunohistochemical evaluation of small cell lung cancer. <i>Lung Cancer</i> , 2019, 137, 108-112.	2.0	10
78	Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor \geq T790M-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment. <i>Journal of Clinical Medicine</i> , 2020, 9, 1762.	2.4	10
79	Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small cell lung cancer: A retrospective study. <i>Thoracic Cancer</i> , 2022, 13, 173-181.	1.9	10
80	A novel potent inhibitor of inducible nitric oxide synthase, ONO-1714, reduces hyperoxic lung injury in mice. <i>Respiratory Medicine</i> , 2007, 101, 793-799.	2.9	9
81	Expression of Akt Kinase-Interacting Protein 1, a Scaffold Protein of the PI3K/PDK1/Akt Pathway, in Pancreatic Cancer. <i>Pancreas</i> , 2014, 43, 1093-1100.	1.1	9
82	Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma. <i>Cancer Science</i> , 2015, 106, 102-107.	3.9	9
83	Association of immune checkpoint inhibitors with respiratory infections: A review. <i>Cancer Treatment Reviews</i> , 2020, 90, 102109.	7.7	9
84	Prognostic impact of pleural effusion in EGFR-mutant non-small cell lung cancer patients without brain metastasis. <i>Thoracic Cancer</i> , 2019, 10, 557-563.	1.9	8
85	Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation. <i>Cancers</i> , 2019, 11, 365.	3.7	8
86	Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study). <i>Clinical Lung Cancer</i> , 2019, 20, e402-e406.	2.6	8
87	Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092784.	3.2	8
88	The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 663612.	2.8	8
89	Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib. <i>Diagnostics</i> , 2021, 11, 2170.	2.6	8
90	Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis. <i>International Journal of Clinical Oncology</i> , 2009, 14, 468-472.	2.2	7

#	ARTICLE	IF	CITATIONS
91	Metastatic renal cell carcinoma complicated with diffuse alveolar hemorrhage: a rare adverse effect of sunitinib. <i>International Journal of Clinical Oncology</i> , 2010, 15, 638-641.	2.2	7
92	Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab. <i>Internal Medicine</i> , 2021, 60, 3585-3588.	0.7	7
93	A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma. <i>Translational Lung Cancer Research</i> , 2022, 11, 238-249.	2.8	7
94	Antiangiogenic therapies for malignant pleural mesothelioma. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 740.	3.0	6
95	Treatment rationale and design of the SPIRAL study. <i>Medicine (United States)</i> , 2018, 97, e11081.	1.0	6
96	Androgen replacement therapy for cancer-related symptoms in male: result of prospective randomized trial (ARTFORM study). <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 831-842.	7.3	6
97	Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report. <i>Respiratory Medicine Case Reports</i> , 2018, 25, 261-263.	0.4	5
98	Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial. <i>Investigational New Drugs</i> , 2018, 36, 903-910.	2.6	5
99	Treatment rationale and design of the RAMNITA study. <i>Medicine (United States)</i> , 2018, 97, e11084.	1.0	5
100	Advanced G-CSF-producing non-small cell lung cancer not otherwise specified, with favourable response to pembrolizumab monotherapy. <i>Respirology Case Reports</i> , 2020, 8, e00625.	0.6	5
101	Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR T790M mutation in non-small cell lung cancer cells. <i>Cancer Medicine</i> , 2022, 11, 944-955.	2.8	5
102	Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer. <i>Investigational New Drugs</i> , 2019, 37, 291-296.	2.6	4
103	Phase II Study on Biweekly Combination Therapy of Gemcitabine plus Carboplatin for the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2020, 25, 208-e417.	3.7	4
104	Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2437-2446.	2.5	4
105	TTF-1 and c-MYC-defined Phenotypes of Large Cell Neuroendocrine Carcinoma and Delta-like Protein 3 Expression for Treatment Selection. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, 29, 313-320.	1.2	4
106	The Impact of Immune-related Adverse Events on the Effect of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer. <i>Japanese Journal of Lung Cancer</i> , 2019, 59, 128-136.	0.1	4
107	Abstract PR7: Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor-resistance in EML4-ALK lung cancer cells. <i>Clinical Cancer Research</i> , 2012, 18, PR7-PR7.	7.0	4
108	A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumors. <i>International Immunopharmacology</i> , 2022, 108, 108775.	3.8	4

#	ARTICLE	IF	CITATIONS
109	Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100353.	1.1	4
110	Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019, 24, 1033-e617.	3.7	3
111	Rationale and design of a phase II trial of osimertinib as first-line treatment for elderly patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer (SPIRAL-0) <i>TJ ETQq1 1 0.784314 rgBT /Overlo</i>	3.7	3
112	A Phase II Study of S-1 and Paclitaxel Combination Therapy as a First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019, 24, 459.	3.7	3
113	Respiratory complications of Stevens-Johnson syndrome (SJS): 3 cases of SJS-induced obstructive bronchiolitis. <i>Allergy International</i> , 2020, 69, 465-467.	3.3	3
114	Synchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 followed by pancrelipase treatment of pancreatic exocrine insufficiency. <i>JOP: Journal of the Pancreas</i> , 2013, 14, 515-20.	1.5	3
115	The Quality of Life of Patients with Suspected Lung Cancer before and after Bronchoscopy and the Effect of Mirtazapine on the Depressive Status. <i>Internal Medicine</i> , 2020, 59, 1605-1610.	0.7	3
116	The Role of Percutaneous Needle Biopsy in Differentiation of Renal Tumors. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 1081-1086.	1.3	2
117	<i>in vivo</i> imaging xenograft models for the evaluation of anti-brain tumor efficacy of targeted drugs. <i>Cancer Medicine</i> , 2017, 6, 2972-2983.	2.8	2
118	Androgen replacement therapy for cancer-related symptoms in male advanced cancer patients: study protocol for a randomised prospective trial (ARTFORM study). <i>Journal of Medical Investigation</i> , 2017, 64, 202-204.	0.5	2
119	Prognostic factors in older patients with wild-type epidermal growth factor receptor advanced non-small cell lung cancer: a multicenter retrospective study. <i>Translational Lung Cancer Research</i> , 2021, 10, 193-201.	2.8	2
120	HGF-MET in Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer. <i>Current Signal Transduction Therapy</i> , 2011, 6, 228-233.	0.5	2
121	Cancer of Unknown Primary Site in which Tumor Marker-Oriented Chemotherapy was Effective and Pancreatic Cancer was Finally Confirmed at Autopsy. <i>Internal Medicine</i> , 2009, 48, 1651-1656.	0.7	1
122	Effective combined therapy with ramucirumab for advanced pulmonary pleomorphic carcinoma. <i>Respirology Case Reports</i> , 2018, 6, e00372.	0.6	1
123	The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations. <i>BMC Cancer</i> , 2018, 18, 1241.	2.6	1
124	Rationale and design of a phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in epidermal growth factor receptor-mutated advanced non-small cell lung cancer (SPIRAL-Daco study). <i>Translational Lung Cancer Research</i> , 2019, 8, 519-523.	2.8	1
125	Phase I/II Study of Docetaxel and S-1 in Previously-Treated Patients with Advanced Non-Small Cell Lung Cancer: LOGIK0408. <i>Journal of Clinical Medicine</i> , 2019, 8, 2196.	2.4	1
126	Diverse Receptor Tyrosine Kinase Phosphorylation in Urine-Derived Tubular Epithelial Cells from Autosomal Dominant Polycystic Kidney Disease Patients. <i>Nephron</i> , 2020, 144, 525-536.	1.8	1

#	ARTICLE	IF	CITATIONS
127	Histone deacetylase inhibitor OBPA€801 and amrubicin synergistically inhibit the growth of squamous cell lung carcinoma by inducing mitochondrial ASK1â€dependent apoptosis. International Journal of Oncology, 2020, 56, 848-856.	3.3	1
128	Abstract 1692: The impact of neutrophil/lymphocyte ratio as the predictive marker to anti-PD-1 antibody treatment in NSCLC patients. , 2018, , .		1
129	Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2985-2994.	2.5	1
130	P1.03-032 In vivo Imaging Models for Preclinical Screening of Molecular Targeted Drugs against Brain Metastasis. Journal of Thoracic Oncology, 2017, 12, S561-S562.	1.1	0
131	An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer. Medicine (United States), 2018, 97, e12660.	1.0	0
132	Randomized Phase II Study of Firstâ€Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Nonâ€Small Cell Lung Cancer: LOGIK0801. Oncologist, 2020, 25, e1146-e1157.	3.7	0
133	MO2-5 Impact of pre-treatment AXL expression on EGFR-TKI efficacy in EGFR-mutated non-small cell lung cancer patients. Annals of Oncology, 2021, 32, S295.	1.2	0
134	SY13-3 Novel therapeutic strategies for drug-tolerance in NSCLC with driver oncogenes. Annals of Oncology, 2021, 32, S258.	1.2	0
135	Abstract A178: Role of tumor and hostâ€derived HGF in drug resistance to EGFR inhibitors in EGFR activating mutationâ€positive lung cancer. , 2009, , .		0
136	Abstract 626: Therapeutic effect of HGF inhibitors against HGF-induced EGFR-TKI resistance in lung cancer harboringEGFRmutations. , 2010, , .		0
137	Abstract 629: Hepatocyte growth factor induces resistance to an irreversible epidermal growth factor receptor inhibitor inEGFR-T790M mutant lung cancer. , 2010, , .		0
138	Abstract 1730: Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs inEGFRmutant lung cancer. , 2011, , .		0
139	Abstract B21: E7050, a Met kinase inhibitor, reverses three different mechanisms of hepatocyte growth factor-induced resistance to tyrosine kinase inhibitors in EGFR mutant lung cancer cells. Clinical Cancer Research, 2012, 18, B21-B21.	7.0	0
140	Abstract 1896: Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer. , 2012, , .		0
141	Abstract 1907: Heat shock protein 90 inhibition overcomes hepatocyte growth factor-triggering resistance to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer by decreasing client protein expression and angiogenesis. , 2012, , .		0
142	Abstract 2762: Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations. , 2014, , .		0
143	Abstract 3555: Akt kinase-interacting protein1 as a potential therapeutics target in CREB1 signaling in malignant pleural mesothelioma. , 2015, , .		0
144	Abstract 4763: Targeted therapy by MET inhibitors against small-cell lung cancer with aberrant activation of HGF/MET pathway. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
145	Abstract 4661: Loss of LKB1 in NSCLC confers sensitivity to MEK inhibition by regulating activation of AKT-FOXO3 pathway. , 2016, , .		0
146	Two cases of primary malignant melanoma of the esophagus. Skin Cancer, 2017, 32, 6-11.	0.0	0
147	Abstract 5535: Effect of LKB1 activity on the sensitivity to PI3K/mTOR inhibitor in non-small-cell lung cancer. , 2017, , .		0
148	Abstract 2839: Notch3-dependent beta-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC. , 2018, , .		0
149	Abstract 5843: The efficacy of a histone deacetylase inhibitor in combination with a MEK inhibitor in lung cancer cells harboring RAS mutations. , 2018, , .		0
150	Abstract 4899: The impact of theEGFR-T790M mutation detection by re-biopsy in EGFR mutant NSCLC patients in the retrospective analysis. , 2019, , .		0
151	Abstract 3996: Search for prognosis prediction factors in treatment selection for elderly patients with EGFR negative advanced stage non-small cell lung cancer patients. , 2019, , .		0
152	Abstract 4036: The efficacy of immune checkpoint inhibitors in patients with EGFR mutated non small cell lung cancer in retrospective analysis. , 2019, , .		0
153	Abstract 4306: Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients. , 2020, , .		0
154	Abstract 313: AXL confers intrinsic resistance to osimertinib and the emergence of tolerant cells. , 2019, , .		0
155	Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology, 0, , .	2.5	0